Iterum Therapeutics plc (ITRMF) Net Equity Issued and Repurchased (2018 - 2025)

Iterum Therapeutics has reported Net Equity Issued and Repurchased for 5 years, with the latest figure at $5.4 million in Q3 2025.

• On a quarterly basis, Net Equity Issued and Repurchased changed 0.24% year-over-year to $5.4 million in Q3 2025; TTM through Sep 2025 was $26.6 million, a 98.52% increase from a year earlier, with the FY2024 full-year figure at $26.7 million, up 2481.33% from the prior year.
• Net Equity Issued and Repurchased was $5.4 million for Q3 2025 at Iterum Therapeutics, up from $957000.0 in the prior quarter.
• The five-year high for Net Equity Issued and Repurchased was $13.9 million in Q4 2024, with the low at $10000.0 in Q3 2023.
• Average Net Equity Issued and Repurchased over 3 years is $3.7 million, with a median of $957000.0 recorded in 2025.
• The largest YoY upside for Net Equity Issued and Repurchased was 54200.0% in 2024 against a maximum downside of 16.5% in 2024.
• Over 3 years, Net Equity Issued and Repurchased stood at $589000.0 in 2023, then surged by 2256.03% to $13.9 million in 2024, then tumbled by 60.96% to $5.4 million in 2025.
• The last three Net Equity Issued and Repurchased figures came in at $5.4 million (Q3 2025), $957000.0 (Q2 2025), and $6.4 million (Q1 2025), per Business Quant data.